Transaction DateRecipientSharesTypePriceValue
17th November 2020David J Matlin441Grant/award etc.$0.00
28th October 2020David J Matlin4,587,647Open or private sale$32.70$150,000,000.14
1st October 2020Joseph Mannello180,000Grant/award etc.$0.00
12th August 2020David J Matlin6,900,000Open or private sale$30.05$207,345,000.00
20th July 2020Robert J Hariri15,300Exercise of in-the-money or at-the-money derivatives securities (usually options)$3.57$54,621.00
31st March 2020Joseph Mannello16,529Open or private purchase$0.00
31st March 2020Eric Zaltas16,529Grant/award etc.$0.00
31st March 2020Louis J. Aronne29,752Grant/award etc.$0.00
31st March 2020Christopher Pechock45,455Grant/award etc.$0.00
31st March 2020Christopher C Dewey6,611Open or private purchase$0.00
Myos Rens Technology
Myos Rens Technology logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

MYOS RENS Technology, Inc. engages in the discovery, development, and commercialization of advanced nutrition products, functional foods, and other technologies. Its primary product is Fortetropin, a proprietary bioactive composition derived from fertilized egg yolk.

Ticker: MYOS
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1402479
Employees: 15
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags